Interferon alfacon-1 microbiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Microbiology
Antiviral Activity in Cell Culture
The antiviral activity of INFERGEN, alone or in combination with ribavirin, against HCV or HCV-derived replicons in cell culture has not been determined.
Resistance
HCV genotypes show wide variability in their response to interferon/ribavirin based therapies. Genetic changes associated with the variable response have not been identified. It has been reported that certain regions of the HCV genome, especially a region in the NS5B protein called IFN-sensitive determining region, may play a role in determination of a patient’s response to interferon treatment.
Cross-resistance
The homology between interferon alfacon-1 and other type-I interferons, and the clinical responses for the different HCV genotypes are consistent with cross-resistance.[1]
References
- ↑ "INFERGEN (INTERFERON ALFACON-1) INJECTION [KADMON PHARMACEUTICALS, LLC]". Retrieved 8 January 2014.
Adapted from the FDA Package Insert.